REG - Ondine Biomedical - Appointment of new Chief Financial Officer

Ondine BiomedicalAnnouncement

16/01/2024 08:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240116:nRSP8435Za&default-theme=true

RNS Number : 8435Z  Ondine Biomedical Inc.  16 January 2024

16 January 2024

 

ONDINE BIOMEDICAL INC.

 

("Ondine Biomedical", "Ondine" or the "Company")

 

Appointment of new Chief Financial Officer

Canadian life sciences company Ondine Biomedical Inc. (LON: OBI) has appointed
Joseph P. ("JP") Errico as Chief Financial Officer. i  JP will be responsible
for managing and developing Ondine's finance function, as well as managing the
capital markets interface, participating in discussions with large health
systems and customers, and working closely with the management team on overall
growth strategy, both from a financial and operational perspective.

JP has successfully founded and sold (or taken public) several medical device
and pharmaceutical companies, including ElectroCore, Fastenetix, K2 Medical
Systems, AD4-Pharma, E2, and SpineCore, with his patented products generating
over $20 billion in sales.

Carolyn Cross, CEO and founder of Ondine commented:

"We are delighted that JP has agreed to join Ondine at this exciting time. His
experience in finance, capital markets and developing medtech companies will
be invaluable as we move forward with our international expansion and
achieving FDA approval in conjunction with our partner HCA Healthcare."

JP Errico commented:

"Ondine represents a unique opportunity to create shareholder value while
heading off one of humanity's greatest health threats, antimicrobial
resistance. I am proud to be joining an excellent team of professionals as
Ondine brings this critically needed technology to the world."

JP's educational background includes an undergraduate degree in Aeronautical
Engineering from the Massachusetts Institute of Technology and graduate
degrees in both Law and Mechanical/Materials Engineering from Duke University.
He is also a trained patent attorney.

*ENDS*

Enquiries:

 

 Ondine Biomedical Inc.
 Angelika Vance, Corporate Communications                     +001 (604) 838 2702

 Singer Capital Markets (Nominated Adviser and Joint Broker)
 Aubrey Powell, Asha Chotai, Sam Butcher                      +44 (0)20 7496 3000

 RBC Capital Markets (Joint Broker)
 Rupert Walford, Kathryn Deegan                               +44 (0)20 7653 4000

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy, Amanda Bernard                             +44 (0)77 1000 5910

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life science company innovating in the
field of photodisinfection therapies. Ondine has a pipeline of investigational
products, based on its proprietary photodisinfection platform, in various
stages of development. Ondine's nasal photodisinfection technology is approved
in several jurisdictions under the brand name Steriwave®. It has been awarded
the CE mark and, in the US, has been granted Qualified Infectious Disease
Product designation and Fast Track status by the FDA. Products beyond nasal
photodisinfection include therapies for a variety of medical indications such
as chronic sinusitis, ventilator-associated pneumonia, burns, and other
indications.

 i  A non-board position.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAEAPFKFENLEEA